What counts as recurrent UTI and who is affected?

Recurrent UTI is two or more symptomatic, culture-confirmed urinary infections within six months, or three or more within twelve months. It affects roughly one in four women after an initial infection, with a second peak after the menopause driven by oestrogen withdrawal, vaginal atrophy, and incomplete bladder emptying. Men are rarely affected without an underlying cause — benign prostatic hypertrophy, prostatitis, or a urinary stone — and almost always warrant specialist assessment. Children with recurrent UTI need paediatric review to exclude vesico-ureteric reflux.

What investigations does my GP need to arrange?

Before every treatment course, a midstream urine (MSU) culture confirms the organism and antibiotic sensitivities, and distinguishes reinfection from relapse. For the recurrent pattern itself, a renal tract ultrasound and post-void bladder residual measurement look for anatomical causes. In postmenopausal women, a pelvic examination identifies prolapse. HbA1c screens for diabetes. Cystoscopy is reserved for red flags: blood in the urine, an unusual organism, symptoms persisting after treatment, or new-onset UTI over age 40 in a smoker.

What is methenamine hippurate and why is it preferred to antibiotics?

Methenamine hippurate (Hiprex) 1 g twice daily is a non-antibiotic tablet that releases formaldehyde in acidic urine, suppressing bacterial growth without contributing to antibiotic resistance. The ALTAR randomised trial (BMJ 2022) found it was not inferior to low-dose antibiotic prophylaxis for reducing recurrent UTI episodes, with fewer antibiotic courses overall. Australian antimicrobial-stewardship guidance positions it as the preferred prophylactic option when behavioural strategies are insufficient. It is on the PBS general schedule with no authority code required.

What does vaginal oestrogen do for postmenopausal women with recurrent UTI?

After menopause, oestrogen withdrawal thins the vaginal lining, raises vaginal pH, and allows coliform bacteria to colonise the area around the urethra. Local vaginal oestrogen — estriol cream applied nightly for two weeks, then twice weekly, or an estradiol pessary — restores a healthy lactobacillus environment and roughly halves recurrence rates according to Cochrane meta-analysis. Because it acts locally with minimal systemic absorption, it is generally well tolerated. Discuss any history of breast cancer with your GP before starting.

Do cranberry products and D-mannose actually work?

Cochrane 2023 found standardised cranberry tablets containing at least 36 mg of proanthocyanidins daily reduced symptomatic UTI episodes by about 26% in women with recurrent infections — a modest but real benefit. Cranberry juice is usually at insufficient dose. D-mannose 2 g daily blocks the adhesion protein that E. coli uses to attach to the bladder lining; an early randomised trial found it comparable to low-dose nitrofurantoin prophylaxis, though later results have been more mixed. Both are safe adjuncts, not substitutes for culture, specific antibiotics, or vaginal oestrogen where indicated.

Is long-term antibiotic prophylaxis safe?

Continuous low-dose prophylaxis — trimethoprim 100 mg nightly or nitrofurantoin 50 mg nightly — is effective, reducing recurrence by roughly half. However it accumulates costs: resistance in gut bacteria, risk of Clostridioides difficile colitis, and for nitrofurantoin used beyond six months, rare but serious pulmonary fibrosis and hepatitis. Australian guidelines recommend non-antibiotic strategies first. If prophylaxis is needed, a six-month trial followed by an attempt at cessation is the usual approach. Nitrofurantoin long-term requires an annual chest review and cannot be used when kidney function is significantly reduced.

Recurrent urinary tract infection

Recurrent UTI: the Australian general practice approach to prevention

By Dr HB Lo, FACRRM Reviewed 14 June 2026 10 min read

Recurrent UTI — defined as two or more culture-confirmed urinary infections in six months, or three or more in twelve months — affects around 25–30% of women after a first infection. Most episodes are reinfection with a new organism rather than a persistent one.

Australian general practice guidelines now front-load non-antibiotic prevention: adequate hydration, vaginal oestrogen for postmenopausal women, and methenamine hippurate (Hiprex). Antibiotic prophylaxis is effective as second-line but accumulates resistance and adverse effects, so it is reserved for when non-antibiotic strategies prove insufficient.

A urinary tract infection is uncomfortable enough once. When the same pattern repeats — two infections in six months, or three in a year — it becomes recurrent UTI (rUTI), and the management shifts from treating individual episodes to understanding and preventing them.

Recurrent UTI is overwhelmingly a condition affecting women. Lifetime UTI risk in women is around 50%, and of those who have one infection, roughly one in four will experience a recurrence within six months. This is not simply bad luck — specific biological mechanisms make some women more prone, and targeting those mechanisms is the foundation of modern management in Australian general practice.

The treatment landscape has shifted in the past decade. The emphasis now is on identifying modifiable drivers — vaginal atrophy, incomplete bladder emptying, inadequate hydration, contraception method — and addressing them with non-antibiotic strategies before reaching for prophylactic antibiotics. This article follows Therapeutic Guidelines (eTG) Antibiotic and RACGP guidance on recurrent UTI.

A. Core clinical — the AU general practice framework

Definition and taxonomy

Recurrent UTI requires symptomatic, culture-confirmed infections meeting one of these criteria:

≥2 UTIs within 6 months, or
≥3 UTIs within 12 months

Two key patterns determine management:

Reinfection — a new episode with a different organism, or the same organism reappearing more than two weeks after completing treatment. This is the most common pattern in women. The bladder has been cleared; a new colonisation event has occurred.

Relapse — the same organism returning within two weeks of finishing treatment, suggesting inadequate eradication, a persistent reservoir (stone, abscess, prostatic focus), or an unusual pathogen. Relapse requires different workup.

The distinction matters because reinfection is managed with prevention strategies; relapse almost always warrants imaging and specialist input to identify the source.

Who gets recurrent UTI

Recurrent UTI is overwhelmingly a condition affecting women — the female-to-male ratio is approximately 30:1 in pre-menopausal adults. A second peak occurs after menopause.

Pre-menopausal women:

Frequent sexual intercourse (each episode carries risk — the pattern is sometimes called “honeymoon cystitis”)
Spermicide or diaphragm contraception
New sexual partner in the past 12 months
First UTI before age 15
Genetic susceptibility (Lewis blood group non-secretor status, toll-like receptor variants)

Postmenopausal women:

Vaginal atrophy from oestrogen withdrawal (raises pH, reduces lactobacillus, allows periurethral colonisation)
Cystocele or pelvic organ prolapse
Post-void residual urine over 100 mL
Diabetes mellitus
Urinary incontinence
History of catheterisation

All ages:

Urinary tract stones, anatomical variants (duplex system, stricture), or foreign bodies
Neurogenic bladder — multiple sclerosis, Parkinson disease, spinal cord injury, diabetic cystopathy
Poorly controlled diabetes or significant immunosuppression (transplant medications, biologics)

History and examination

A thorough initial assessment covers: episode frequency and pattern; any relationship to intercourse or other activities; symptoms at each episode (was there ever fever or flank pain suggesting pyelonephritis?); prior urine culture results and organisms; antibiotics used and response; contraception method; menopausal status; pelvic floor symptoms; fluid intake; voiding habits; and comorbidities including diabetes, renal disease, and neurological conditions.

Examination includes blood pressure, BMI, urinalysis, and MSU collection. In postmenopausal women, pelvic examination assesses for prolapse, vaginal atrophy, and pelvic floor function.

Workup

The RACGP recommends a structured workup:

At every acute episode:

Midstream urine (MSU) microscopy, culture, and sensitivities before starting antibiotics — essential to track organisms, detect emerging resistance, and distinguish reinfection from relapse.

At the initial recurrent-pattern review:

Renal tract ultrasound — excludes stones, hydronephrosis, significant post-void residual
Post-void bladder residual measurement (over 100 mL is abnormal)
HbA1c or fasting glucose (diabetes is a major driver)
Pelvic examination in postmenopausal women

Cystoscopy and CT urogram are reserved for red flags:

Macroscopic haematuria
Persistent unusual organism (not E. coli or Staphylococcus saprophyticus)
Symptoms not resolving after adequate treatment
Age over 40 with new-onset symptoms and a smoking history
Clinical suspicion of fistula, stone, or bladder tumour

Treating the acute episode

Per eTG Antibiotic, first-line options for uncomplicated cystitis in women:

Agent	Dose	Duration
Trimethoprim	300 mg daily	3 days
Nitrofurantoin	100 mg four times daily	5 days
Cefalexin	500 mg four times daily	5 days

Always culture before treating in recurrent UTI. Fluoroquinolones (ciprofloxacin) are reserved for pyelonephritis or documented resistance — Australian antimicrobial stewardship guidance advises against empirical fluoroquinolone use for uncomplicated lower UTI. Pyelonephritis — fever, rigors, flank pain, systemic unwell — requires 10–14 days and possible inpatient management.

Prevention hierarchy

Australian guidelines step through prevention from least to most antibiotic exposure:

Behavioural strategies — hydration, voiding hygiene, contraception change
Vaginal oestrogen (postmenopausal) — the largest single effect in this group
Non-antibiotic prophylaxis — methenamine hippurate (Hiprex) 1 g twice daily
Antibiotic prophylaxis — only after steps 1–3 have failed or are not tolerated

B. Evidence appraisal — what the trials show

Hydration

Hooton and colleagues (JAMA Internal Medicine 2018) randomised pre-menopausal women who typically drank less than 1.5 litres of water daily to increase intake by an additional 1.5 litres per day. The extra water group averaged 1.7 UTI episodes per year, compared to 3.2 in the control group — close to a halving of the annual rate. This is low-cost, universally applicable, and strongly supported as first-line advice.

Vaginal oestrogen

Cochrane meta-analysis (Perrotta et al) found vaginal oestrogen reduced recurrent UTI by approximately 58% in postmenopausal women (risk ratio 0.42). This is one of the largest single-intervention effects in recurrent UTI prevention. Local vaginal oestrogen — estriol 0.1% cream (Ovestin) nightly for two weeks then twice weekly, or estradiol 10 µg pessary (Vagifem) twice weekly — delivers oestrogen to the vaginal and periurethral epithelium with minimal systemic absorption. Both are on the PBS general schedule without authority code. The Estring vaginal ring provides continuous delivery but is private-only in Australia.

Methenamine hippurate — the ALTAR trial

The ALTAR trial (BMJ 2022, Harding et al) randomised 240 women with recurrent UTI to methenamine hippurate 1 g twice daily or daily low-dose antibiotic prophylaxis for 12 months. Methenamine hippurate was non-inferior: 0.89 episodes per person-year versus 1.38 in the antibiotic group. The methenamine arm received significantly fewer antibiotic courses over the year. This trial provided robust randomised evidence that a non-antibiotic strategy performs as well as antibiotics while preserving the antibiotic stewardship principle.

Cranberry products

Cochrane 2023 (Williams et al) — 50 trials, nearly 9,000 participants — found cranberry products reduced symptomatic UTI episodes by 26% in women with recurrent UTI (risk ratio 0.74, moderate-quality evidence). The benefit was concentrated in products providing at least 36 mg proanthocyanidins (PACs) daily. Cranberry juice typically provides insufficient PAC concentration. Standardised PAC tablets are available over the counter.

D-mannose

Kranjčec et al (World J Urol 2014) randomised 308 women to D-mannose 2 g daily, nitrofurantoin 50 mg daily, or no prophylaxis. D-mannose was comparable to nitrofurantoin (recurrence 14.6% vs 18.5% vs 60.8%). D-mannose competes with uroepithelial receptors for the FimH adhesin that E. coli uses to colonise the bladder lining. Subsequent trials have been more mixed. It remains a safe and reasonable over-the-counter adjunct.

C. Non-antibiotic prevention — practical implementation

These strategies can be stacked, beginning with the strongest evidence:

Hydration: target 2 litres of water daily unless cardiac or renal contraindication applies. Keeping a water bottle visible throughout the day improves adherence.

Voiding hygiene: void every 2–3 hours during the day; void promptly after intercourse; wipe front to back; avoid prolonged bladder retention; avoid sitting in wet clothing or swimwear for extended periods.

Contraception review: spermicide and diaphragm contraception significantly increase recurrent UTI risk. Switching to hormonal contraception or barrier methods without spermicide can substantially reduce episodes in affected women.

Vaginal oestrogen (postmenopausal): estriol 0.1% cream (Ovestin) nightly for two weeks, then twice weekly ongoing; or estradiol 10 µg pessary (Vagifem) twice weekly. Improvement typically takes 4–8 weeks. Long-term use is appropriate for ongoing prevention. NPS MedicineWise provides patient-friendly information on local vaginal oestrogen. Discuss any breast cancer history with your GP before starting.

Methenamine hippurate (Hiprex): 1 g twice daily with meals. Works best in acidic urine — do not take simultaneously with urinary alkalinisers (such as potassium citrate). Generates formaldehyde locally and does not create antibiotic resistance. Side effects are uncommon but may include mild nausea.

Cranberry: standardised tablets with ≥36 mg PACs daily (check product label). Juice is usually at insufficient dose.

D-mannose: 2 g dissolved in water daily. Safe and well tolerated; a reasonable adjunct.

Probiotics: Lactobacillus rhamnosus and L. reuteri (oral or vaginal) — low-level evidence but safe, particularly in postmenopausal women after oestrogen-deprived disruption of vaginal flora.

Pelvic floor physiotherapy: for women with voiding dysfunction or prolapse contributing to incomplete bladder emptying, referral to a continence physiotherapist via the Continence Foundation of Australia directory addresses this as a driver.

D. Australian operations

Antibiotic prophylaxis

When non-antibiotic strategies are insufficient or not tolerated, per eTG Antibiotic:

Regimen	Dose	Notes
Trimethoprim	100 mg nightly	Community E. coli resistance ~30% nationally — culture every episode
Nitrofurantoin	50 mg nightly	Avoid eGFR <45; annual chest review if using >6 months
Cefalexin	250 mg nightly	Pregnancy-safe
Post-coital	Trimethoprim 300 mg or nitrofurantoin 50–100 mg within 2 hours of intercourse	Intercourse-related patterns only
Self-start	3-day course pre-supplied; patient initiates at first symptom	Culture before starting if possible

Trial for 6 months, then attempt cessation and reassess. AURA 2023 documents trimethoprim resistance approaching 30% in community E. coli nationally — reinforcing the case for culturing every episode.

MBS billing

Item 23 — acute UTI consultation
Item 36 — initial recurrent-pattern workup (typically ≥20 minutes)
Item 44 — complex recurrent UTI with multiple comorbidities
Item 721/723 — GP Management Plan and Team Care Arrangement for diabetes-complicated recurrent UTI
Item 10997 — practice nurse review (Hiprex technique, vaginal oestrogen application)
Items 707/715 — health assessments (75+ and Aboriginal and Torres Strait Islander patients)

Referral thresholds

Setting	When
Urology	Men; macroscopic haematuria; anatomical lesion; persistent same organism; suspected stone, tumour, or fistula
Urogynaecology	Prolapse; post-hysterectomy voiding dysfunction; mesh complications
Renal physician	Chronic kidney disease with recurrent UTI; transplant
Infectious Diseases	Multi-resistant organism; significant immunocompromise
Continence physiotherapist	Voiding dysfunction; pelvic floor contributors to incomplete emptying

E. Special populations

Postmenopausal women: vaginal oestrogen is the most effective single intervention and should be offered to all eligible women. Post-void residual over 100 mL or significant prolapse warrants urogynaecology review.

Pregnant women: UTI in pregnancy carries risk of preterm labour and ascending pyelonephritis. All pregnant women should have MSU culture at booking and at 28 weeks. Treat all symptomatic infections — cefalexin 500 mg four times daily for 5 days is first-line. Avoid trimethoprim in the first trimester (folate antagonism) and nitrofurantoin at term (neonatal haemolysis risk). Confirm clearance with repeat MSU 1–2 weeks after treatment. Continuous cefalexin prophylaxis 250 mg nightly is appropriate for women with recurrent UTI or pyelonephritis during pregnancy.

Men: recurrent UTI in men is almost always complicated and warrants urology referral. Consider chronic bacterial prostatitis — this typically requires 4–6 weeks of trimethoprim or a fluoroquinolone guided by sensitivities. An elevated PSA in the context of active UTI should be rechecked 4–6 weeks after the infection has resolved.

Older adults and residential aged care: asymptomatic bacteriuria is very common in elderly and residential-care populations and does not benefit from antibiotic treatment. Confusion alone without localising urinary symptoms is not sufficient to diagnose UTI — unnecessary antibiotic treatment drives resistance and C. difficile risk in this setting.

Diabetes and SGLT2 inhibitors: optimise glycaemic control. People using SGLT2 inhibitors have a modestly increased risk of urogenital infections — weigh against substantial cardiometabolic benefits. Any severe or unusual genitourinary infection (including Fournier’s gangrene) should prompt urgent review and medication discussion.

When to escalate

Fever, rigors, flank pain, or vomiting — suspect pyelonephritis; same-day urgent assessment; consider inpatient management
Pregnancy with UTI symptoms — treat promptly and confirm clearance with repeat MSU
Macroscopic haematuria persisting after treatment — urgent urology referral for cystoscopy
Suspected sepsis — Emergency Department immediately
Male recurrent UTI — urology referral (almost always a structural or functional cause)
Children — paediatric review to exclude vesico-ureteric reflux and dysfunctional voiding
Multi-resistant organism — Infectious Diseases consultation
Recurrent UTI despite adequate step-wise prophylaxis — specialist workup to exclude bladder pathology

What this article is and is not

This is general health information drawn from Australian clinical guidelines — Therapeutic Guidelines (eTG) Antibiotic, RACGP guidance on recurrent UTI, and ACSQHC antimicrobial stewardship resources — and is not personal medical advice. It does not create a doctor–patient relationship. Decisions about investigation, prevention strategy, and prescribing are made individually with your own GP and specialist.

For consumer-friendly information: HealthDirect — Urinary tract infections, Better Health Channel — UTI, Continence Foundation of Australia.

Sources cited

Frequently asked questions

What counts as recurrent UTI and who is affected?

Recurrent UTI is two or more symptomatic, culture-confirmed urinary infections within six months, or three or more within twelve months. It affects roughly one in four women after an initial infection, with a second peak after the menopause driven by oestrogen withdrawal, vaginal atrophy, and incomplete bladder emptying. Men are rarely affected without an underlying cause — benign prostatic hypertrophy, prostatitis, or a urinary stone — and almost always warrant specialist assessment. Children with recurrent UTI need paediatric review to exclude vesico-ureteric reflux.
What investigations does my GP need to arrange?

Before every treatment course, a midstream urine (MSU) culture confirms the organism and antibiotic sensitivities, and distinguishes reinfection from relapse. For the recurrent pattern itself, a renal tract ultrasound and post-void bladder residual measurement look for anatomical causes. In postmenopausal women, a pelvic examination identifies prolapse. HbA1c screens for diabetes. Cystoscopy is reserved for red flags: blood in the urine, an unusual organism, symptoms persisting after treatment, or new-onset UTI over age 40 in a smoker.
What is methenamine hippurate and why is it preferred to antibiotics?

Methenamine hippurate (Hiprex) 1 g twice daily is a non-antibiotic tablet that releases formaldehyde in acidic urine, suppressing bacterial growth without contributing to antibiotic resistance. The ALTAR randomised trial (BMJ 2022) found it was not inferior to low-dose antibiotic prophylaxis for reducing recurrent UTI episodes, with fewer antibiotic courses overall. Australian antimicrobial-stewardship guidance positions it as the preferred prophylactic option when behavioural strategies are insufficient. It is on the PBS general schedule with no authority code required.
What does vaginal oestrogen do for postmenopausal women with recurrent UTI?

After menopause, oestrogen withdrawal thins the vaginal lining, raises vaginal pH, and allows coliform bacteria to colonise the area around the urethra. Local vaginal oestrogen — estriol cream applied nightly for two weeks, then twice weekly, or an estradiol pessary — restores a healthy lactobacillus environment and roughly halves recurrence rates according to Cochrane meta-analysis. Because it acts locally with minimal systemic absorption, it is generally well tolerated. Discuss any history of breast cancer with your GP before starting.
Do cranberry products and D-mannose actually work?

Cochrane 2023 found standardised cranberry tablets containing at least 36 mg of proanthocyanidins daily reduced symptomatic UTI episodes by about 26% in women with recurrent infections — a modest but real benefit. Cranberry juice is usually at insufficient dose. D-mannose 2 g daily blocks the adhesion protein that E. coli uses to attach to the bladder lining; an early randomised trial found it comparable to low-dose nitrofurantoin prophylaxis, though later results have been more mixed. Both are safe adjuncts, not substitutes for culture, specific antibiotics, or vaginal oestrogen where indicated.
Is long-term antibiotic prophylaxis safe?

Continuous low-dose prophylaxis — trimethoprim 100 mg nightly or nitrofurantoin 50 mg nightly — is effective, reducing recurrence by roughly half. However it accumulates costs: resistance in gut bacteria, risk of Clostridioides difficile colitis, and for nitrofurantoin used beyond six months, rare but serious pulmonary fibrosis and hepatitis. Australian guidelines recommend non-antibiotic strategies first. If prophylaxis is needed, a six-month trial followed by an attempt at cessation is the usual approach. Nitrofurantoin long-term requires an annual chest review and cannot be used when kidney function is significantly reduced.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.